Transforming GSM Care: How Evidence, Experts, and Advocacy Changed the Label - Episode 86

Transforming GSM Care: How Evidence, Experts, and Advocacy Changed the Label Host: Rachel Rubin, MD Guest: Una Lee, MD In November 2025, the FDA removed the black box warning from estrogen therapies, a significant victory for the AUA and its members, who have long advocated for this change. In this special release brought to you by AUA's Public Policy and Advocacy Team, @drrachelrubin and @dr_unalee take you inside the movement as they unpack the origins of the warning, the modern evidence that contradicts it, the impact on GSM care, and the powerful role urology played in driving this change. If this conversation sparked your interest, check out the AUAUniversity Podcast episode on the new Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025) and explore the evidence and recommendations that helped drive the change to remove the black box warning from estrogen therapies. Don't miss a single episode! Subscribe today by clicking on one of the links below or searching "Leadership and Business" on your favorite podcast app! Apple Podcast: https://podcasts.apple.com/us/podcast/aua-leadership-and-business/id1646701227 YouTube Music: https://music.youtube.com/playlist?list=PLmlqgyiBVx1HGqaUsLmAErH472CyzBlLF Spotify: https://open.spotify.com/show/3jZthzjFAHwRSsV72D4JlL